Skip to headlines
clockwire Search
LIVE
Chiefs to ‘leave’ FNB Stadium until New Year Trachoma: Nigeria cuts at-risk population from 41m to under 5m ​‌‌‌​‍‌‍⁠⁠‍‍‍​⁠⁠⁠​​‌​ First-time buyer mortgages hit highest level in 19 years 2027: Anambra set for Tinubu campaign rally Etihad Airways extends flight cancellations to 2 Saudi cities until Nov 30 Partners seek more funding, collaboration to end open defecation by 2030 GCB trains staff in Mandarin to strengthen services for Chinese businesses Richard Riakporhe calls for Deontay Wilder fight to save ‘trash’ Tyson Fury vs Anthony Joshua card Greece Has the Third-Highest Rate of Severe Material and Social Deprivation in EU Take a look, it's in his book: LeVar Burton writes a memoir LIVE: Ireland v Kosovo, Uefa Nations League Ireland v Kosovo: Boys in Green face must-win Nations League clash at Aviva Hungary v Northern Ireland | Michael O’Neill’s side go for Nations League promotion in Budapest ‘Changed my life forever’: Stroke survivor hails 24/7 thrombectomy access Figure skating-Finland entry ban forces Russian skaters out of Grand Prix event
‹ Back to your news

ENTERTAINMENT

MAIA Biotechnology Reports Consistent Strong Efficacy in Expanded Phase 2 THIO-101 Study in Non-Small Cell Lung Cancer

Covered by 1 source First reported

How each outlet tells it

Nasdaq.comUS · private

MAIA Biotechnology Reports Consistent Strong Efficacy in Expanded Phase 2 THIO-101 Study in Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. announced updated interim efficacy data from Part C of its Phase 2 THIO-101 expansion trial evaluating its novel telomere-targeting therapy, ateganosine, as a third-line (3L)…

Read at Nasdaq.com